File Download
Patent History
- ApplicationUS 11/875271 2007-10-19
- PublicationUS 2008095782 2008-04-24
Patent Family
Supplementary
-
Citations:
- Appears in Collections:
published patent: USE OF LIPOCALIN-2 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET
Title | USE OF LIPOCALIN-2 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET |
---|---|
Priority Date | 2007-10-19 US 11/875271 2006-10-20 US 11/853404P |
Inventors | |
Issue Date | 2008 |
Citation | US Published patent application US 2008095782. Washington, DC: US Patent and Trademark Office (USPTO), 2008 How to Cite? |
Abstract | Methods and compositions for identifying and treating obesity and obesity-induced metabolic disorders are provided. One aspect provides a method for the evaluation of risk and progression of glucose tolerance, insulin resistance and Type 2 diabetes in mammalian subjects. The method includes measuring the concentration of circulating lipocalin-2 in a subject and comparing the measured level to lipocalin-2 to a reference level. Another aspect provides methods of treating insulin resistance, type 2 diabetes and other related complications by administering to a patient a composition that can reduce the circulating levels of lipocalin-2, for example a lipocalin-2 antagonist. |
Persistent Identifier | http://hdl.handle.net/10722/176958 |
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2012-11-30T08:38:51Z | - |
dc.date.available | 2012-11-30T08:38:51Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | US Published patent application US 2008095782. Washington, DC: US Patent and Trademark Office (USPTO), 2008 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/176958 | - |
dc.description.abstract | Methods and compositions for identifying and treating obesity and obesity-induced metabolic disorders are provided. One aspect provides a method for the evaluation of risk and progression of glucose tolerance, insulin resistance and Type 2 diabetes in mammalian subjects. The method includes measuring the concentration of circulating lipocalin-2 in a subject and comparing the measured level to lipocalin-2 to a reference level. Another aspect provides methods of treating insulin resistance, type 2 diabetes and other related complications by administering to a patient a composition that can reduce the circulating levels of lipocalin-2, for example a lipocalin-2 antagonist. | en_HK |
dc.relation.isreferencedby | EP 2300048 (A4) 2011-08-24 | en_HK |
dc.relation.isreferencedby | EP 2300048 (A1) 2011-03-30 | en_HK |
dc.title | USE OF LIPOCALIN-2 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET | en_HK |
dc.type | Patent | en_US |
dc.description.nature | published_or_final_version | en_US |
dc.contributor.inventor | Xu, A | en_HK |
dc.contributor.inventor | Wang, Y | en_HK |
dc.contributor.inventor | Lam, KSL | en_HK |
patents.identifier.application | US 11/875271 | en_HK |
patents.description.assignee | UNIV HONG KONG | en_HK |
patents.description.country | United States of America | en_HK |
patents.date.publication | 2008-04-24 | en_HK |
patents.date.application | 2007-10-19 | en_HK |
patents.date.priority | 2007-10-19 US 11/875271 | en_HK |
patents.date.priority | 2006-10-20 US 11/853404P | en_HK |
patents.description.cc | US | en_HK |
patents.identifier.publication | US 2008095782 | en_HK |
patents.relation.family | US 2008095782 (A1) 2008-04-24 | en_HK |
patents.relation.family | US 7645616 (B2) 2010-01-12 | en_HK |
patents.relation.family | US 2010310578 (A1) 2010-12-09 | en_HK |
patents.relation.family | WO 2008049330 (A1) 2008-05-02 | en_HK |
patents.description.kind | A1 | en_HK |
patents.type | Patent_published | en_HK |